Health Trials

About this trial

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory malignant hematological tumors.

It is an early exploratory clinical study of the safety, tolerability and initial efficacy in the treatment of relapsed or refractory malignant hematological tumors.

Eligibility criteria

Qualifiers

Age ≥ 18 years old, gender unrestricted;

Confirmed diagnosis of relapsed/refractory malignant hematological tumors, including B-ALL, B-cell lymphoma and multiple myeloma;

ECOG performance status score 0-2, with an expected survival period of ≥ 3 months;

Absolute neutrophil count (ANC) ≥ 600/μL (no use of granulocyte colony-stimulating factor [G-CSF] within 1 week before screening, or no use of pegylated G-CSF within 2 weeks before screening); ③ Platelet count ≥ 50,000/μL; ④ Lymphocyte count ≥ 500/μL;

Disqualifiers

History of hematopoietic stem cell transplantation: Received allogeneic or autologous hematopoietic stem cell transplantation within 3 months before administration;

Received treatment related to vesicular stomatitis virus glycoprotein (VSVG) pseudotyped virus in the past;

Had severe and uncontrolled infections (bacterial, viral, fungal, etc.) within the screening period;

Had symptomatic heart failure or other serious cardiac diseases (such as severe arrhythmia);

Trial design

Treatments tested in this trial

  • Invivo CAR-T

Treatment groups

24 Participants
are divided into 1 treatment group

Locations

1
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China KunmingYunnan, China

Sponsors and collaborators

Chongqing Precision Biotech Co., Ltd

Lead sponsor

Source ClinicalTrials.gov